Buy & Sell Schwab US Large Cap Growth ETF (SCHG) – Schwab US Large Cap Growth ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Sector/ThematicSector
- -7.38%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 16% Buy | 84% SellTrading Activity
- 18 daysTypical Hold Time
Over the past 52 weeks, Schwab US Large Cap Growth ETF has traded between a low of $27.81 and a high of $35.3, highlighting its annual price range. Over the past three months, Schwab US Large Cap Growth ETF has recorded a drawdown of -7.38%, reflecting recent price volatility. On average, investors hold Schwab US Large Cap Growth ETF for approximately 18 days, indicating typical investor behavior on the platform.
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Most Recent News
Defiance ETFs launches SPCQ, a 2x inverse leveraged ETF targeting daily SpaceX stock declines.
Defiance ETFs introduced the Defiance Daily Target 2X Short SpaceX ETF (SPCQ), designed to provide investors with double inverse exposure to SpaceX's daily stock price movements. This ETF aims to deliver -200% of SpaceX's daily returns, allowing inve...

Halper Sadeh LLC probes fairness of recent major company sales and mergers for shareholders.
Halper Sadeh LLC, an investor rights law firm, is investigating whether shareholders of Open Lending Corporation, Nuvalent, Organon & Co., and SUNation Energy are receiving fair deals in their companies' recent sales or mergers. The firm suggests ins...

Global GLP-1 receptor agonist market to reach $95.3B by 2035, growing at 12.1% CAGR driven by diabetes and obesity demand.
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
